1. Home
  2. ANPA vs VERU Comparison

ANPA vs VERU Comparison

Compare ANPA & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rich Sparkle Holdings Limited Ordinary Shares

ANPA

Rich Sparkle Holdings Limited Ordinary Shares

N/A

Current Price

$1.16

Market Cap

47.0M

Sector

N/A

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

N/A

Current Price

$2.09

Market Cap

41.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANPA
VERU
Founded
2016
1971
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.0M
41.9M
IPO Year
2024
1996

Fundamental Metrics

Financial Performance
Metric
ANPA
VERU
Price
$1.16
$2.09
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $25.67
AVG Volume (30 Days)
18.1K
★ 136.0K
Earning Date
09-30-2026
12-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.14
$2.04
52 Week High
$180.64
$7.33

Technical Indicators

Market Signals
Indicator
ANPA
VERU
Relative Strength Index (RSI) 26.46 39.63
Support Level N/A $2.09
Resistance Level $2.18 $2.68
Average True Range (ATR) 0.10 0.11
MACD 0.02 -0.00
Stochastic Oscillator 11.34 15.15

Price Performance

Historical Comparison
ANPA
VERU

About ANPA Rich Sparkle Holdings Limited Ordinary Shares

Rich Sparkle Holdings Ltd is a holding company conducting its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (ESG) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through its sole operating subsidiary in Hong Kong. Its segments include Financial printing services such as printing, typesetting and translation, Advisory services including Environmental, Social and Governance Report and Other services.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: